Experts from the LNP Alliance discuss where LNP programs stall, how the field is moving beyond vaccines, and why translation ...
In this Q&A, Ingenza CEO Nick Challoner, discusses how CRDMOs must evolve to help biotech companies accelerate development, ...
Realize safe, scalable, and compliant cell therapies by building analytical strategies that exceed regulatory expectations.
A strategic CDMO partnership brings together scientific expertise, manufacturing capabilities, and shared goals to advance ...
As CGT programs move toward scale, the bigger challenge is no longer capacity alone, but keeping the full supply chain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results